Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.34 |
| ▸ | USP7 | Q93009 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 4/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.32 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.32 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4034708 | 0.85 | SYK (0.39) | SYKMAPK7HRH3HRH4USP7 | |
| SCHEMBL6404740 | 0.84 | SYK (0.34) | SYKMAPK7HRH3DDR1MCHR1 | |
| SCHEMBL21177886 | 0.75 | LMNA (0.35) | SYKESR1ESR2 | |
| SCHEMBL1012831 | 0.74 | ESR2 (0.52) | ESR1ESR2 | |
| SCHEMBL4034080 | 0.71 | IP6K1 (0.40) | SYKMCHR1 | |
| SCHEMBL3056830 | 0.70 | HSD17B13 (0.40) | — | |
| SCHEMBL3178090 | 0.69 | PRKCA (0.42) | SYKESR1ESR2 | |
| SCHEMBL13646422 | 0.68 | TNF (0.56) | — | |
| SCHEMBL3429086 | 0.67 | ESR2 (0.36) | ESR2 | |
| SCHEMBL3177791 | 0.67 | ESR2 (0.42) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1444211-B1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2009-01-21 | — | — | EP | disclosed |
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB | 2007-04-19 | — | — | US | disclosed |
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2005-03-10 | — | — | US | disclosed |
| EP-1444211-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003040109-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ERBB3, ABL1 | SYK 318/4885MAPK7 599/4885HRH3 673/4885 |
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ERBB2, EGFR, ERBB4 | SYK 146/4885MAPK7 412/4885HRH3 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.